Agios Pharmaceuticals
AGIO
31.79
+0.07
+0.22%
Agios Pharmaceuticals
US · AGIO
#2841 by market cap
Listed 1970
31.79
+0.07
+0.22%
Live - 5344 symbols - heartbeat 121s ago
· 2026-10-07 19:54
After-hours
31.79
0.00%
- Market cap
- 1.90B
- P/E (TTM)i
- -4.53
- P/Bi
- 1.85
- EPSi
- -7.12
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on AGIO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 111.82% -0.31pp
- Institutions
- 284
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund67.41%
Hedge Fund33.47%
Private Company4.39%
Public Company4.09%
VC/PE Fund1.31%
Individual/Insider1.11%
Insurance Company0.73%
Government Pension Fund0.42%
Top holders as of 2026-06-30
BlackRock
10.81% · 6.46M sh
Farallon Capital Management, L.L.C.
9.91% · 5.92M sh
State Street Global Advisors
5.92% · 3.53M sh
Lynx1 Capital Management LP
5.71% · 3.41M sh
D. E. Shaw & Co., L.P.
5.20% · 3.11M sh
Vanguard Capital Management, LLC
5.16% · 3.08M sh
Vanguard Portfolio Management, LLC
4.85% · 2.90M sh
Armistice Capital LLC
4.02% · 2.40M sh
Erste Asset Management GmbH
3.61% · 2.15M sh
Macquarie Investment Management Business Trust
3.54% · 2.11M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 39 buys · 11 sells
| Name | Role | Stake |
|---|---|---|
| Brian Goff | Chief Executive Officer | 0.31% |
| Jacqualyn Fouse | Chair of the Board of Directors | 0.26% |
| Cecilia Jones | Chief Financial Officer | 0.09% |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 0.09% |
| James Burns | Corporate Secretary & Chief Legal Officer | 0.08% |
| Tsveta Milanova | Chief Commercial Officer | 0.08% |
| David Scadden | Independent Director | 0.03% |
| Maykin Ho | Independent Director | 0.03% |
| Cynthia Smith | Independent Director | 0.03% |
| Rahul Ballal | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-03 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Automatic Disposition | -30,000 | $30.48 |
| 2026-07-07 | Jay Backstrom | Director | Other Acquisition | +1,447 | -- |
| 2026-06-30 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -4,007 | $37.56 |
| 2026-06-30 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Retained | +4,368 | -- |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Jeffrey Capello | Independent Director | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Jay Backstrom | Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jay Backstrom | Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Maykin Ho | Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Maykin Ho | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Maykin Ho | Independent Director | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Brian Goff | Chief Executive Officer | Other Derivative Acquisition | +39,000 | -- |
| 2026-06-17 | Brian Goff | Chief Executive Officer | Other Derivative Disposition | -39,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.